When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma.
2/5 보강
TL;DR
Preclinical and clinical evidence supporting combination therapies integrating immune checkpoint inhibitors with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) remains a valid option, and this review summarizes the preclinical and clinical evidence supporting this approach.
OpenAlex 토픽 ·
Renal cell carcinoma treatment
Cancer Immunotherapy and Biomarkers
Immunotherapy and Immune Responses
Preclinical and clinical evidence supporting combination therapies integrating immune checkpoint inhibitors with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) rem
APA
Sebastiano Buti, Betty Dalla Valle, et al. (2026). When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma.. Critical reviews in oncology/hematology, 221, 105238. https://doi.org/10.1016/j.critrevonc.2026.105238
MLA
Sebastiano Buti, et al.. "When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma.." Critical reviews in oncology/hematology, vol. 221, 2026, pp. 105238.
PMID
41771460 ↗
Abstract 한글 요약
Combination therapies integrating immune checkpoint inhibitors (ICIs) with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), or dual ICI regimens, currently represent the standard of care for advanced clear cell renal cell carcinoma (ccRCC). However, in most favorable-risk patients according to the IMDC classification-particularly those with a low disease burden and without disease-related symptoms-first-line monotherapy with VEGFR-TKIs remains a valid option. This review summarizes the preclinical and clinical evidence supporting this approach, with the aim of guiding oncologists in personalizing therapy while minimizing overtreatment and toxicity.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.